A multi-center phase 2a trial of the CXCR4 inhibitor motixafortide (BL-8040) (M) in combination with pembrolizumab (P) and chemotherapy (C), in patients with metastatic pancreatic adenocarcinoma (mPDAC)

Autores: Hidalgo, M.; Macarulla, T.; Semenisty, V. ; Borazanci, E. ; Feliu, J.; Ponz Sarvisé, Mariano; Gutiérrez-Abad, D.; Oberstein, P.; Alistar, A.; Munoz, A.; Geva, R.; Guillen-Ponce, C.; Peled, A.; Chaney, M.; Glicko-Kabir, Irit.; Shemesh-Darvish, L. ; Ickowicz, D.; Sorani, E.; Kadosh, S. E.; Vainstein-Haras, A.; Bockorny, B.